Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Amycretin showed 13.1% weight loss in Phase I trial
Side-effects similar to other incretin-based treatments
Decision on Phase III trial pending study data next year
Adds shares in paragraph 4, detail on production in paragraphs 16-17
By Jacob Gronholt-Pedersen and Maggie Fick
COPENHAGEN, Sept 11 (Reuters) -Novo Nordisk NOVOb.CO said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%.
That compared to weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials of Wegovy.
Shares in Novo, which presented full data from the Phase I study at the European Association for the Study of Diabetes meeting in Madrid, were trading up 2.4% at 1307 GMT.
"What we see in the study period is a 13.1% weight loss with a side effect profile comparable to what we normally see with incretin-based therapy, so primarily gastrointestinal side effects," Martin Holst Lange, Novo's head of development, said in an interview ahead of the presentation.
One serious but non-fatal adverse event was reported during the trial with 60 participants, according to the data presented at the conference. There were no reports of severe side-effects for patients taking amycretin, while there were a total of 242 reports of mild and moderate side effects.
Amycretin targets the same gut hormone that Wegovy mimics, known as GLP-1, but also a pancreas hormone called amylin that affects hunger.
In the amycretin trial, the side effects were related to gastrointestinal discomfort, including nausea and vomiting, similar to those seen in trials of its other medicines from the same GLP-1 drug class, the company said.
Novo is also developing another two-drug combination known as CagriSema that also targets the amylin hormone, which the company has said has a potential of up to 25% weight loss.
"The data that I've seen so far suggests that amycretin has at least the same weight-loss potential as CagriSema," Lange said.
In the study, overweight or obese patients without diabetes received increasing doses of amycretin, starting from 3 milligrams and up to a final dose of two 50 mg pills, Novo said.
Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4% on average, while those taking the maximum dose of 2x50 mg lost 13.1% of their starting weight, the company said. The weight loss did not plateau by the end of 12 weeks.
That compared to an average weight loss of 1.1% among those taking a placebo.
The data warrants further clinical development, Lange said.
A decision on whether to skip a Phase II trial for amycretin and proceed directly to phase III - typically the final stage of human testing before seeking approval - will be taken once data from an early study on a subcutaneous version of the drug is ready next year.
Existing obesity drugs like Wegovy and Eli Lilly's LLY.N Zepbound are injectable. Pills require larger amounts of active ingredients, which can make them more costly to produce but are often favoured by patients.
Both companies are racing to increase output of the active ingredients needed to make their hotly demanded GLP-1 obesity drugs.
Novo's shares have increased more than three-fold since June 2021, when it launched Wegovy in the U.S., but have shed 15% since peaking in June this year.
Around 40% of Novo's valuation is pinned to its pipeline of experimental drugs, analysts at Berenberg said last week.
Last year, Novo became Europe's most valuable listed company, ahead of LVMH LVMH.PA.
Reporting by Jacob Gronholt-Pedersen in Copenhagen and Maggie Fick in London; Editing by Bill Berkrot, Louise Heavens and Jan Harvey
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
